Analysts’ updated eps estimates for Friday, September 8th:

BNP Paribas SA (EPA:BNP) had its buy rating reissued by analysts at Citigroup Inc..

Coherus BioSciences (NASDAQ:CHRS) had its buy rating reaffirmed by analysts at Maxim Group. The firm currently has a $20.00 price target on the stock. The analysts wrote, “The challenge for biosimilar makers of humira is not similar efficacy, it’s winning the IP battle with AbbVie. Coherus, in our view, was ideally positioned to win the biosimilar race as it was founded with a focus on IP.””

Cloudera (NASDAQ:CLDR) had its buy rating reaffirmed by analysts at Stifel Nicolaus. The firm currently has a $24.00 target price on the stock.

Conn’s (NASDAQ:CONN) had its buy rating reissued by analysts at Stifel Nicolaus. The firm currently has a $26.00 price target on the stock, up from their previous price target of $20.00.

Credit Suisse Group (NYSE:CS) had its buy rating reissued by analysts at Citigroup Inc..

Donaldson (NYSE:DCI) had its hold rating reissued by analysts at Stifel Nicolaus. The firm currently has a $45.00 price target on the stock, down from their previous price target of $48.00.

Vinci SA (EPA:DG) had its neutral rating reissued by analysts at Barclays PLC.

Proofpoint (NASDAQ:PFPT) had its outperform rating reiterated by analysts at Wedbush. The firm currently has a $104.00 price target on the stock.

Sabra Healthcare REIT (NASDAQ:SBRA) had its buy rating reaffirmed by analysts at Cantor Fitzgerald. Cantor Fitzgerald currently has a $30.00 price target on the stock. The analysts wrote, “We expect investors to be pleased that SBRA’s restructuring of selected underperforming leases acquired in last months combination with CCP appears to eliminate the poor coverage issues at Signature and other operators, and demonstrate substantially more accretion from CCP than we had assumed.””

United Natural Foods (NASDAQ:UNFI) had its sector perform rating reaffirmed by analysts at Royal Bank Of Canada. They currently have a $34.00 target price on the stock.

Verona Pharma PLC American Depositary Share (NASDAQ:VRNA) had its outperform rating reaffirmed by analysts at Wedbush. They currently have a $33.00 target price on the stock.

Get Analysts' Upgrades and Downgrades Daily - Enter your email address below to receive a concise daily summary of analysts' upgrades, downgrades and new coverage with MarketBeat.com's FREE daily email newsletter.